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TRANSPLANT (BMT)
Friedman JY1, Reed SD1, Glendenning A2, Schulman KA1
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OBJECTIVES: BMT is an important technology used 
in the treatment of cancer patients. Cost estimates for 
this procedure vary, and mostly derive from estimates
developed early in the dissemination of the technology.
Our objective was to describe the costs associated with
BMT.
METHODS: Using 1999 MarketScan data, we analyzed
commercial non-Medicare inpatient claims for patients
who underwent initial BMT. Costs are comprised of total
gross payments to all providers associated with the 
admission, including physicians and hospital facilities.
RESULTS: 69 patients were eligible for analysis. 42%
and 29% of the sample were from the North Central or
Southern region of the U.S. Mean age was 44 years. The
mean and median total claims paid for BMT were
$83,027 and $76,826, respectively (95% CI: $72,520,
$93,534). The average length of stay (LOS) was 25.6 
days (95% CI: 22.9, 28.4). Average costs increased as 
LOS increased ($49,501 for LOS 0–15, $74,384 for LOS
16–30, $99,050 for LOS 31–45, and $169,431 for LOS
> 45). The most frequent diagnoses for the sample were:
multiple myeloma 19%, non-Hodgkin’s lymphoma 16%,
other types of cancer 13%, myeloma 10%, and chronic
myeloid leukemia 9%. The average cost of BMT was 
signiﬁcantly more expensive for patients with a diagnosis
of leukemia (e.g. chronic myeloid leukemia) ($94,473)
versus patients with other types of cancer ($72,535) (95%
CI for the difference: $1,639, $42,498). Mean costs were
higher for patients who died ($111,025) versus those
patients discharged to their home, either under self-care
($80,618) or medical supervision ($65,291).
CONCLUSIONS: We found that costs for BMT vary by
diagnosis, LOS, and patient outcomes. Our estimate for
BMT appears to be less expensive than initial estimates
($250,000). However, our analysis only included costs 
for initial BMT whereas other cost estimates include 
additional costs, such as costs for rehospitalizations,
follow-up care and outpatient medications.
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Prophylactic granulocyte-colony stimulating factor 
(G-CSF) reduces the incidence and duration of
chemotherapy-induced neutropenia (CIN), thereby reduc-
ing the risk of complications, dose delays, and reductions
that may compromise outcomes. A published risk thresh-
old model for the cost-effective use of prophylactic G-CSF
used direct costs derived from randomized clinical trials.
With direct cost estimates of $1,000 per day, prophylac-
tic G-CSF becomes cost-effective when the risk of hospi-
talization exceeds 40%, and this value is reﬂected in
current ASCO guidelines for CSF use (Lyman et al, JNCI,
1993). An updated analysis incorporating total institu-
tional costs of $1750 per day reduces the risk threshold
to 23% (Lyman et al, Eur J Cancer, 1998).
OBJECTIVE: Utilizing indirect cost estimates for neu-
tropenia obtained from a pilot study (Calhoun at al, The
Oncologist, 2001), the risk threshold model was modiﬁed
to incorporate indirect costs.
METHODS: For parameters describing patients not
receiving G-CSF, the indirect costs were fully added to 
the direct institutional costs. For the parameters describ-
ing patients receiving prophylactic G-CSF, the indirect
costs were adjusted by the reduced incidence of severe
neutropenia (50%), and further by the reduced probabil-
ity of the development of febrile neutropenia (50%)
related to G-CSF use. The new model was evaluated for
indirect cost estimates ranging from $1,000 through
$5,000 per episode. Patient out-of-pocket and indirect
costs for an episode of severe neutropenia were estimated
at $5,176 per episode, excluding hospitalizations
(Calhoun at al, The Oncologist, 2001).
RESULTS: The addition of indirect costs yields a reduced
threshold for prophylactic G-CSF use from 23% (no 
indirect costs) to 8% ($5,000 indirect costs).
CONCLUSION: The incorporation of indirect costs into
economic models provides a more complete assessment 
of the impact of prophylactic G-CSF from a societal 
perspective. Additional study of the model assumptions
and indirect cost estimates are needed to further improve
the decision model.
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OBJECTIVES: Rituximab (MabThera) combined with
CHOP chemotherapy (R-CHOP) signiﬁcantly prolongs
event-free and overall survival of patients with diffuse
large B-cell lymphoma (DLCL) (GELA LNH 98–5 Study).
We estimated the cost-effectiveness of R-CHOP.
METHODS: The analyses were based on a randomized-
controlled trial comparing R-CHOP with CHOP, from a
French health system perspective. Patients (n = 399) were
